Neurological Institute Outcomes
Surgical Quality Improvement
Brain Tumor Surgery Outcomes
Brain Tumor Surgery ACS NSQIP Outcomes
January 1, 2020 – December 31, 2020
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall brain tumor surgery ACS NSQIP performance benchmarked against 226 participating sites.
| Brain Tumor (226 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 238 | 1.26% | 1.87% |
| 30 Day Morbidity | 238 | 12.61% | 10.33% |
| Cardiac | 238 | 0.84% | 0.62% |
| Pneumonia | 238 | 2.10% | 1.90% |
| Unplanned Intubation | 238 | 2.94% | 1.91% |
| Ventilator > 48 Hours | 238 | 2.52% | 1.66% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 238 | 4.20% | 3.92% |
| Urinary Tract Infection (UTI) | 238 | 1.68% | 1.32% |
| Surgical Site Infection (SSI) | 238 | 3.78% | 2.08% |
| Sepsisᵃ | 238 | 4.20% | 1.77% |
| Return to Operating Room (ROR) | 238 | 5.04% | 5.24% |
American College of Surgeons National Surgical Quality Improvement Program, 2021.
ACS NSQIP® Semiannual Report July 8, 2021, Chicago: American College of Surgeons.
ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.
